StemCord
StemCord is a Singapore-headquartered private cord blood bank founded in 2002 that collects, processes, and cryopreserves umbilical cord blood and cultured cord stem cells for expectant-parent subscribers across Singapore, the Philippines, and Indonesia.
- Company typePrivate
- Founded2002
- HeadquartersManila, Philippines
- Headcount11–50
- GTM typeB2C
- OfferingServices
What StemCord does
StemCord is a privately-held, autologous cord blood bank incorporated in March 2002 and headquartered in Singapore, with regional operations in the Philippines (opened 2020) and Indonesia. It collects, processes, and cryopreserves umbilical cord blood containing haemopoietic stem cells (HSCs) and, since the 2015 Stem Med partnership, mesenchymal stem cells (MSCs) cultured from cord tissue using its proprietary CultureFIRST method, which the company claims yields approximately 8x more viable cells than traditional frozen-tissue extraction. Samples are processed in an ISO Class 5 clean room, coded under the ISBT 128 standard, and stored in vapour-phase liquid nitrogen at -180 deg C or colder across two separate cryo bags at two distinct laboratory locations in Singapore. The company was founded and is led by practising haematologists, medical oncologists, and a nephrologist with direct bone-marrow and stem-cell transplantation programme experience at Singapore General Hospital and National University Hospital.
The commercial model is direct-to-consumer, targeting expectant parents in the third trimester of pregnancy (around 28-32 weeks). Customers enrol through sales consultants at baby and parenting fairs (e.g. Momzilla Fair, Edamama New Mama Expo), via the company's website, or a 24-hour hotline, with pricing published at PHP 75/day for combined cord blood and cord stem cell banking on instalment plans of 3, 6, 9, or 12 months and a long-term storage commitment of up to 21 years. Bundled into enrolment is the StemCord Bonus Covers suite of medical insurance-style add-ons covering transplant expenses, alternative stem cell sourcing, HLA testing, continuity of storage until age 21, and international courier charges. As of 2017 over 40,000 cord blood units had been stored with the company, and growth in stored inventory is implied by five consecutive NetCord-FACT accreditations (2011, 2014, 2017, 2021, 2026) and ongoing regional sales coverage in Metro Manila and Jakarta.
Distribution and patient education rely on a mix of field sales consultants, regional offices in Singapore, Manila, and Jakarta, an in-person presence at pregnancy expos, free pregnancy webinars (launched 2020, first session drew 1,000+ attendees), brand collaborations with parenting-product partners, and a content/blog library on the company website. The company employs 11-50 people across Singapore, the Philippines, and Indonesia; carries a Singapore Ministry of Health cord-blood banking licence; and complies with Singapore's Personal Data Protection Act. Revenue figures are not publicly disclosed, and no external funding rounds, acquisitions, or AI/ML product capabilities are evidenced in the source data.
StemCord firmographics
Firmographics- Name
- StemCord
- Legal name
- STEMCORD SG PHILS. CORPORATION
- Website
- https://stemcord.com.ph
- Company type
- Private
- Founded year
- 2002
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- StemCord is a Singapore-headquartered private cord blood bank founded in 2002 that collects, processes, and cryopreserves umbilical cord blood and cultured cord stem cells for expectant-parent subscribers across Singapore, the Philippines, and Indonesia.
- Ownership category
- akta.pro rank
StemCord industry classification
Industry- Product category
- Cord Blood Banking Services
- NAICS
- Blood and Organ Banks (621991)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Cell & Tissue Banking (biobanking, cord blood/tissue) (HLAAAGAE)
- akta.pro secondary industries
- Stem Cell–Based Regenerative Therapies (HLAAAGAA), Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE)
Keywords
Where StemCord is headquartered
LocationHeadquarters
- HQ city
- Manila
- HQ country
- Philippines
- HQ region
- Asia
Offices3 records
Markets served
StemCord business model
Business model- GTM type
- B2C
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain
Revenue model
- Cord Blood Banking Services: Private cord blood banking services including enrollment, collection kit, laboratory processing, maternal blood testing, viability testing, and storage. Services are provided on a long-term commitment basis with payment plans available.
- Cord Stem Cells Banking: Banking of Mesenchymal Stem Cells (MSCs) cultured from umbilical cord tissue, processed using CultureFIRST method and stored alongside cord blood.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Cord Blood Banking from ₱75/day |
| Subscription | Monthly | Cord Blood and Cord Stem Cells Combined Banking |
Go-to-market motion1 record
Distribution channels4 records
Marketing channels6 records
StemCord product offering
Product offeringCore offering
StemCord is an autologous, private cord blood bank that collects, processes, and cryopreserves umbilical cord blood containing Haematopoietic Stem Cells (HSCs) and umbilical cord tissue-derived Mesenchymal Stem Cells (MSCs) for long-term family storage. The company provides enrollment, collection kits, laboratory processing, maternal blood testing, viability testing, and multi-location cryogenic storage at -180°C or colder using its proprietary CultureFIRST method and dual-bag dual-site storage architecture.
Product overview
StemCord offers a private cord blood and cord stem cells banking service headquartered in Singapore with operations in the Philippines and Indonesia. The core offering consists of two integrated banking services: Cord Blood Banking for Haemopoietic Stem Cells (HSCs) and Cord Stem Cells Banking for Mesenchymal Stem Cells (MSCs). The proprietary CultureFIRST processing method cultures stem cells before storage to maximize yield. Storage is provided in two bags at two separate Singapore locations for security. Comprehensive insurance coverage (StemCord Bonus Covers) is included with enrollment, covering transplant expenses, medical testing, and international courier services. Pricing starts at PHP 75/day with flexible payment plans.
Differentiator
Problem solved
Functional benefit
Brands
- CultureFIRST: StemCord's proprietary process that cultures cord stem cells before storage, providing 8x more cell yield than frozen tissue storage.
- StemCord Bonus Covers
Products and services
- Cord Blood Banking Private cord blood banking service that collects, processes, and stores Haemopoietic Stem Cells (HSCs) from umbilical cord blood for expectant parents and families. HSCs are used to treat over 80 diseases including blood cancers, bone marrow disorders, and immune deficiencies.
- Cord Stem Cells Banking Banking service for Mesenchymal Stem Cells (MSCs) extracted and cultured from umbilical cord tissue (Wharton's Jelly) for expectant parents and families. MSCs have regenerative potential for treating conditions such as heart disease, diabetes, spinal cord injuries, and autoimmune disorders.
- StemCord Bonus Covers Suite of medical insurance packages bundled with enrollment: QualityPLUS (alternative stem cell source expenses), Transplant Medicare (autologous transplant medical expenses), AssuredPlus (HLA testing and viability assays), Care21 (storage coverage until child turns 21 if parent passes), and WorldWidePlus (international courier charges).
- Enrollment and Collection Kit Complete enrollment process including contract signing, receipt of cord blood/cord stem cells collection kit, and payment processing. The collection kit contains all materials required for hospital cord blood collection immediately after delivery.
Quantifiable outcome
- 8x higher cell yield with CultureFIRST compared to frozen cord tissue extraction
- +2 more outcomes
Companies that use StemCord
Customer profileNamed customers6 records
Segments4 records
Ideal customer profiles3 records
StemCord technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
Feature4 records
StemCord partnerships and signals
Strategic signalScale indicators5 records
Recent moves11 records
Expansion highlights6 records
StemCord competitors and assessment
Company assessmentBroad incumbents
- ViaCord: US private cord blood and cord tissue bank owned by Revvity (formerly PerkinElmer). Comparable end-to-end autologous banking service with established brand and physician channel — benchmark for mature-market positioning.
- Cryo-Cell International: US-listed private cord blood bank with international licensee network. Comparable autologous banking model and provides a public benchmark for valuation and unit economics in the cord blood banking category.
- Cord Blood Registry (CBR): Largest US private newborn stem cell company, part of the Cooper Companies portfolio. Offers private cord blood and cord tissue banking with extensive consumer marketing — useful comparable for scale, product packaging and pricing benchmarks.
- China Cord Blood Corporation: One of the largest cord blood banking operators in China, listed in New York. Operates a multi-province network of licensed cord blood banks — broad incumbent in cord blood storage, demonstrating scaled economics StemCord has not yet reached.
Regional players
- Smart Cells International: UK-based private stem cell bank with international presence. Comparable autologous cord blood and cord tissue banking offering — relevant comp for service packaging, insurance add-ons and cross-border distribution patterns.
- Cellsafe International: Indonesia-focused private stem cell and cord blood bank. Comparable autologous cord blood and MSC banking services but concentrated in Indonesia, overlapping directly with StemCord's PT StemCord Indonesia Sehat operations.
Emerging players
- Singapore Cord Blood Bank: Singapore-based public cord blood bank (non-profit). Comparable storage operations and laboratory capabilities but offers donated public banking rather than autologous storage — a substitute for cost-sensitive expectant parents considering StemCord.
Direct peers
- Stemlife Berhad: Malaysian private cord blood bank providing collection, processing and long-term storage of umbilical cord blood. Comparable service offering, similar regulatory environment and overlapping target customer segment of expectant parents in the region.
- CryoCord: Malaysian private cord blood and cord tissue bank offering HSC and MSC cryopreservation services. Closely comparable business model (private family banking, multi-product offering, regional Southeast Asia distribution) competing in adjacent geography.
- Cordlife Group: SGX-listed private cord blood banking group headquartered in Singapore with regional operations across Asia. Direct competitor offering autologous and family cord blood banking with similar FACT-Netcord-aligned positioning and overlapping customer base of expectant parents in Southeast Asia.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
StemCord social profiles
Digital presenceStemCord compliance and trust
Trust signalCompliance5 records
StemCord financial estimates
Financial estimateRevenue estimate
Valuation estimate
StemCord leadership team
Management profileNumber of profiles
Profiles5 records
StemCord subsidiaries and ownership
Company hierarchySubsidiaries2 records
StemCord funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
StemCord M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about StemCord
What does StemCord do?
StemCord is an autologous, private cord blood bank that collects, processes, and cryopreserves umbilical cord blood containing Haematopoietic Stem Cells (HSCs) and umbilical cord tissue-derived Mesenchymal Stem Cells (MSCs) for long-term family storage. The company provides enrollment, collection kits, laboratory processing, maternal blood testing, viability testing, and multi-location cryogenic storage at -180°C or colder using its proprietary CultureFIRST method and dual-bag dual-site storage architecture.
Is StemCord a public or private company?
StemCord is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was StemCord founded?
StemCord was founded in 2002. It employs 11 to 50 people.
Where is StemCord based?
StemCord is headquartered in Manila, Philippines, in the Asia region.
How does StemCord make money?
Two revenue lines are on record. Cord Blood Banking Services are the primary driver. The others are cord Stem Cells Banking.
Who are StemCord's main competitors?
Broad incumbents on record are ViaCord, Cryo-Cell International, Cord Blood Registry (CBR) and China Cord Blood Corporation. Regional players are Smart Cells International and Cellsafe International. Singapore Cord Blood Bank is listed as an emerging player. Direct peers are Stemlife Berhad, CryoCord and Cordlife Group.
Does StemCord have an API?
No public API is recorded for StemCord.
What industry is StemCord in?
StemCord's product category is Cord Blood Banking Services. Its primary akta.pro industry code is HLAAAGAE, Cell & Tissue Banking (biobanking, cord blood/tissue), with a secondary code of HLAAAGAA, Stem Cell–Based Regenerative Therapies. Its NAICS code is 621991 and its SIC code is 2836.